These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 1685125)

  • 21. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
    Colado MI; Murray TK; Green AR
    Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro.
    Gobbi M; Moia M; Pirona L; Ceglia I; Reyes-Parada M; Scorza C; Mennini T
    J Neurochem; 2002 Sep; 82(6):1435-43. PubMed ID: 12354291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR; McKenna DJ; Peroutka SJ
    Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.
    Nagai F; Nonaka R; Satoh Hisashi Kamimura K
    Eur J Pharmacol; 2007 Mar; 559(2-3):132-7. PubMed ID: 17223101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine.
    Monte AP; Marona-Lewicka D; Cozzi NV; Nichols DE
    J Med Chem; 1993 Nov; 36(23):3700-6. PubMed ID: 8246240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
    Johnson MP; Frescas SP; Oberlender R; Nichols DE
    J Med Chem; 1991 May; 34(5):1662-8. PubMed ID: 1674539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds.
    Colado MI; Green AR
    Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices.
    Fitzgerald JL; Reid JJ
    Eur J Pharmacol; 1990 Nov; 191(2):217-20. PubMed ID: 1982265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.
    Gu XF; Azmitia EC
    Eur J Pharmacol; 1993 Apr; 235(1):51-7. PubMed ID: 8100196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine.
    Farfel GM; Vosmer GL; Seiden LS
    Brain Res; 1992 Nov; 595(1):121-7. PubMed ID: 1361410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).
    Kramer HK; Poblete JC; Azmitia EC
    Neuropsychopharmacology; 1998 Oct; 19(4):265-77. PubMed ID: 9718590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 5-hydroxytryptamine-releasing properties of two epimer quinoline derivatives.
    Le Fur G; Imbault F; Mitrani N; Marquis F; Renault C; Dubroeucq MC; Gueremy C; Uzan A
    Neuropharmacology; 1984 Feb; 23(2A):169-73. PubMed ID: 6717757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine.
    Raiteri M; Del Carmine R; Bertollini A; Levi G
    Eur J Pharmacol; 1977 Jan; 41(2):133-43. PubMed ID: 832672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain.
    Hashimoto K
    Neurosci Lett; 1993 Apr; 152(1-2):17-20. PubMed ID: 7685864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
    Johnson MP; Nichols DE
    Pharmacol Biochem Behav; 1989 May; 33(1):105-8. PubMed ID: 2476831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA).
    Li Q; Murakami I; Stall S; Levy AD; Brownfield MS; Nichols DE; Van de Kar LD
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1261-7. PubMed ID: 8968349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.
    Shimshoni JA; Winkler I; Golan E; Nutt D
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):15-24. PubMed ID: 27650729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats.
    Mokler DJ; Robinson SE; Rosecrans JA
    Eur J Pharmacol; 1987 Jun; 138(2):265-8. PubMed ID: 2887440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.